Efficacy News and Research

RSS

Degrading mutant KRAS protein induces greater lung cancer regression

KRAS is one of the oncogenes most frequently altered in cancer, mutated in approximately one-third of lung adenocarcinomas.

27 May 2026

Blocking sugar modification could boost breast cancer immunotherapy success

Immunotherapies such as so-called checkpoint inhibitors activate the body's own immune system to fight cancer cells and have revolutionized the treatment of many types of tumor.

27 May 2026

Combat Medical highlights patient impact of HIVEC HEAT trial at the American Urological Association Annual Meeting

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced an update on its HIVEC® HEAT FDA registration trial at The American Urological Association (AUA) Annual Meeting.

From Combat Medical 27 May 2026

One-time gene editing cuts LDL cholesterol in early hypercholesterolemia trial

A phase 1 NEJM interim analysis found that a single infusion of the investigational base-editing therapy VERVE-102 produced dose-dependent reductions in circulating PCSK9 protein and LDL cholesterol in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease.

26 May 2026

New study tests vitamin D analog against pancreatic cancer

A small clinical trial led by Dana-Farber Cancer Institute researchers put a Salk Institute idea to the test in patients: that activating the vitamin D receptor can help reshape the protective environment surrounding pancreatic tumors in ways that could make the notoriously difficult-to-treat cancer more vulnerable to therapeutic treatments.

26 May 2026

Study unravels mystery about why physical forces slow cancer growth

Researchers have solved a long-standing mystery about why physical forces slow cancer growth – and the answer could reshape how the disease is treated.

26 May 2026

Roswell Park scientists present five key cancer studies at clinical meeting

The research findings of experts from Roswell Park Comprehensive Cancer Center will be featured during the American Society of Clinical Oncology (ASCO) annual meeting May 29 to June 2 at McCormick Place in Chicago.

25 May 2026

New peptide triggers domino effect to suppress bladder cancer

Recently, a research team led by Professors Dahong Zhang and Qi Zhang from the Urology Department and the Institute of Urology at Zhejiang Provincial People's Hospital and the Translational Medicine Center discovered that a bladder tumor-targeting polyarginine peptide, R11, can directly bind to actin, destabilize the G-actin tetramer, and trigger the cascade breakdown of the actin-plectin-vimentin/ITGβ4 axis (referred to as the "cytoskeletal domino effect").

25 May 2026

Senolytic therapy delays early disc degeneration in mouse model

Targeting senescent cells with dasatinib-quercetin preserves disc structure and modulates degeneration-associated pathways in a mouse model.

25 May 2026

Blood carotenoids offer the clearest signal of fruit and vegetable eating habits

The review finds that several candidate biomarkers may help estimate fruit and vegetable intake more objectively than self-reported dietary tools, but most remain limited by specificity, sampling burden, supplement use, or incomplete validation. Blood and skin carotenoids appear strongest for habitual intake, while vitamin C, folate, urinary flavonoids, hippuric acid, and potassium may be more useful for short-term intake or intervention adherence.

24 May 2026

Researchers uncover immune mechanisms behind polycystic kidney disease progression

A new review has illuminated a critical but often overlooked dimension of autosomal dominant polycystic kidney disease (ADPKD)—its immune microenvironment.

24 May 2026

Pim1 identified as promising therapeutic target for inflammatory arthritis treatment

The research team led by Professor Zhongyu Xie from Sun Yat-sen University revealed a new mechanism by which Pim1 regulated Th17 cell differentiation through mitochondrial metabolism.

22 May 2026

Mitochondrial checkpoint enables dendritic cells to activate T lymphocytes against viruses, tumors

A study led by researchers at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) has identified a mitochondrial "checkpoint" that enables dendritic cells to efficiently activate T lymphocytes against viruses and tumors.

22 May 2026

Combination therapy improves response rates for chronic hepatitis B patients

The optimal management strategy for adults with immune-tolerant (IT) chronic hepatitis B infection remains undefined. This study aimed to investigate the efficacy and predictive factors of a pegylated interferon (Peg-IFN)-based treatment strategy in IT patients with chronic HBV infection.

22 May 2026

Targeting a key protein reduces injury in steatotic liver transplantation

Steatotic donor livers are highly susceptible to post-transplant dysfunction; however, the underlying mechanisms remain incompletely understood.

22 May 2026

Weight loss helps older AF patients slim down, but does not ease symptoms

An 8-month low-calorie diet plus behavioral support helped older adults with overweight or obesity and persistent atrial fibrillation lose weight safely, with no intervention-related serious adverse events. However, the LOSE-AF trial found no meaningful improvement in AF symptoms, rhythm control, AF burden, cardiac remodeling, or further AF procedure rates compared with usual care.

22 May 2026

New eye drop formulation shows promise for dry eye disease

Researchers at Baylor College of Medicine and Okayama University in Japan have developed and tested in mice a promising new eye drop formulation for treating dry eye disease.

21 May 2026

Targeting tumor-specific inflammatory process may prevent drug resistance in colon cancer

Chemotherapy drugs that target a common mutation in colorectal cancer rapidly lose efficacy in patients, leading to relapse.

21 May 2026

Uneven grey matter loss serves as a powerful new biomarker for early neurodegeneration

Universitat Oberta de Catalunya Alzheimer's disease begins to weave a web in the brain and remodel neuronal tissue 15 to 20 years before the first symptoms appear. From the time this happens, however, until the disease is diagnosed and, later, enters an advanced phase, it progresses along a continuum of changes to the brain.

21 May 2026

Oral AD109 improves sleep apnea severity but tolerability remains a challenge

AD109, an investigational once-daily oral combination of aroxybutynin and atomoxetine, significantly improved airway obstruction and oxygenation in adults with mild-to-severe obstructive sleep apnea who could not use PAP therapy. However, symptom improvements did not clearly differ from placebo, and about one in five AD109 recipients discontinued treatment due to adverse events.

21 May 2026